IP Library Granted Patent US 8,889,705
Granted Patent B2
US 8,889,705 · App. 13/488,621 · Granted Nov 18, 2014

Noscapine analogs and their use in treating cancers

Inventors: Harish C. Joshi (Decatur, GA); Ritu Aneja (Lilburn, GA); Surya N. Vangapandu (Smyrna, GA)
Assignee: Emory University
A61K31/4741C07D491/056A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,705
App. No.
13/488,621
Granted
Nov 18, 2014
Kind
B2
Abstract

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyzes pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes.

Claims (6)

1. A method of treating lung cancer comprising administering an effective amount of ((S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-9-bromo-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one) or pharmaceutically acceptable salts thereof to a patient in need of treatment thereof.

2. The method of claim 1 , wherein ((S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-9-bromo-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one) or pharmaceutically acceptable salts thereof are administered orally.

3. The method of claim 1 , wherein ((S)-6,7-dimethoxy-3-((R)-4-methoxy-6-methyl-9-bromo-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one) or pharmaceutically acceptable salts thereof is administered in combination with at least one other anticancer agent.

4. The method of claim 3 , wherein the other anticancer agent is selected from busulfan, cis-platin, mitomycin C, and carboplatin.

5. The method of claim 3 , wherein the other anticancer agent is selected from colchicine, vinblastine, paclitaxel, and docetaxel.

6. The method of claim 3 , wherein the other anticancer agent is selected from doxorubicin and etoposide.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 1, 2014
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034498/0178 →
Continuity (3)
Continuation 12530158
Provisional Application 60904959 · Mar 5, 2007
Related Publication 20130224310A1 · Aug 29, 2013